Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer


Weniger M., Moir J., Damm M., Maggino L., Kordes M., Rosendahl J., ...More

PANCREATOLOGY, vol.20, no.6, pp.1131-1138, 2020 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 20 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1016/j.pan.2020.06.012
  • Journal Name: PANCREATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1131-1138
  • Keywords: FOLFIRINOX, Gemcitabine, Nab-paclitaxel, Neoadjuvant chemotherapy, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, GEMCITABINE, FOLFIRINOX, RESECTION, ADENOCARCINOMA, PHASE-3, DEATHS
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Background: Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis.